July 201619platforms for disease specific applications and for screening drugs with a keen agenda to come up with novel formulations targeting India specific medical conditions. Transcell's defined areas of interest are: Autoimmune disorders, Brain diseases, Cancers and Periodontal diseases.Accomplishing Maximum with Minimum The company has placed its execu-tives in seven cities across India, while the rest of the country is cov-ered through the word-of-mouth of its network of practitioners. These executives directly approach the clinicians' community to explain the latest innovations of Transcell and how the clinicians can lever-age these innovations to their ben-efit promoting storage of stem cells when there is an opportunity to in life. Executives also reach out to eli-gible families visiting hospitals and clinics. Transcell attains traction by disseminating information through both digital and on-site outreach activities. Strongly believing in achieving maximum with minimum base, Tran-scell intends to grow organically by establishing alliances with medical practitioners, rather than growing into a 100 employees company overnight. The company wishes to remain small and establish strong footprint devel-oping novel products and processes in the domain with the first mover advantage. "A leader has to be part of the spectrum of activities that are go-ing on in the organization. I motivate my people by being with them as an employee of Transcell. I enjoy be-ing part of every step in building this technology intensive organization.The purpose of my life is to see Tran-scell technologies translating into the clinics," asserts Dr. Subhadra. But that doesn't mean she has been prior-itizing professional obligations over her personal life. Anyone who listens to Dr. Subhadra's anecdote about her son wanting to become a diamond merchant by selling Transcell can feel the immense love, pride and pas-sion she has vested in her family.Exploring New Territories As the regulatory barriers are slow-ing down the growth of the stem cell industry, Transcell endeavors to formulate an ecosystem in India, for which the company has been provid-ing its expert opinion and global per-spective to bring forth a policy for the country with the benefits reaching to the ailing patients now. Transcell has recently raised investment from In-dian Angels Network for developing patient derived progenitor cellular products for discovering druggable molecules for Cancers and Neurode-generative disorders. Transcell antic-ipates raising series A funding in the next two years for lead optimizations in both the Regenerative medicine and Drug discovery verticals. Keen on strengthening its stem cell storage vertical in Indian mar-ket, the company has already started exploring the East Indian states to offer it's basket of storage services through partnering with local stal-warts. It also endeavors to build a robust intellectual property base from its productization verticals ad-dressing disease. Transcell plans to build the value of the company by collaborating with established in-ternational organizations discover-ing and developing right kind of biological formulations to cure debil-itating diseases of mankind with key technology differentiators.Dr. Subhadra Dravida, Founder & CEOThis pioneering biotech entrepreneur has been instrumental in shaping the company's vision and mission as fully-integrated, innovation-led, emerging enterprise committed to technology advancements and reaching the patient community. With over 17 years of domain experience in commercialization and translating science to business opportunities, she has won national and international grants.Office: HyderabadOfferings/Products: Cryopreservation of Stem Cells, Regenerative Medicine and Drug DiscoveryKey ManagementTranscell wishes to remain small and establish strong footprint developing novel products and processes in the domain with the first mover advantage
< Page 9 | Page 11 >